surmount tirzepatide trials ESC 2025: post-hoc SURMOUNT-5 data affirms tirzepatide's lead in CVD risk reduction In the SURMOUNT-5 phase 3b

Results Study Populations Figure 1 is the flowchart showing cohort construction

Observations with GLP-1 Agonists: Antibody Reduction: The speaker has witnessed significant reductions in Hashimoto's antibodies among patients using GLP-1agonists, indicating their potential role in managing auto-immune thyroid conditions

Both stacks are built on the foundation of optimized magnesium and mineral status

In summary, while CVS has standardized criteria and offers preferred formulary status to some GLP-1s, its net effect in 2026 is still very restrictive coverage: in practice most patient requests are either barred or deferred

During each visit, the size of the target thyroid nodule was measured, and plasma levels of thyroid-stimulating hormone, free thyroxin, and copper

PMID 4279150